Matrix metalloproteinase-2 (MMP-2) and Matrix metalloproteinase-9 (MMP-9) (MMP-2 and MMP-9)

Matrix metalloproteinase-2 (MMP-2) and Matrix metalloproteinase-9 (MMP-9), collectively known as gelatinases, are zinc-dependent endopeptidases that play a critical role in the degradation and remodeling of the extracellular matrix (ECM) [1, 7]. They are primarily responsible for breaking down type IV collagen, a major component of basement membranes, as well as gelatin, elastin, and fibronectin [1, 15]. In healthy tissues, these enzymes are essential for physiological processes such as wound healing, angiogenesis, and embryonic development [7, 9]. However, their dysregulation is a hallmark of various pathological conditions, particularly cancer, where they facilitate tumor invasion, metastasis, and the formation of new blood vessels [10, 19]. Beyond oncology, MMP-2 and MMP-9 are implicated in inflammatory diseases, cardiovascular disorders like atherosclerosis and aneurysms, and neurodegenerative conditions such as multiple sclerosis [3, 16]. Therapeutic targeting of these enzymes has historically focused on broad-spectrum small molecule inhibitors that chelate the catalytic zinc ion, but these efforts were largely hindered by significant side effects, most notably musculoskeletal syndrome [4, 10]. Modern drug development strategies are shifting toward more selective approaches, including monoclonal antibodies and allosteric inhibitors, to minimize off-target toxicity while effectively modulating their activity in disease states [4, 6].

Other names

Gelatinase A (MMP-2)Gelatinase B (MMP-9)72 kDa type IV collagenase (MMP-2)92 kDa type IV collagenase (MMP-9)Neutrophil gelatinase (MMP-9)CLG4ACLG4B

Inhibition of enzyme activity via zinc-binding site chelation, allosteric inhibition of the catalytic domain, binding to secondary binding sites (exosites), prevention of pro-enzyme activation, and downregulation of gene expression [4, 13, 19].